178 related articles for article (PubMed ID: 36842202)
1. Tisotumab vedotin in recurrent or metastatic cervical cancer.
Bogani G; Coleman RL; Vergote I; Raspagliesi F; Lorusso D; Monk BJ
Curr Probl Cancer; 2023 Jun; 47(3):100952. PubMed ID: 36842202
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204/GOG-3023/ENGOT-cx6): a multicentre, open-label, single-arm, phase 2 study.
Coleman RL; Lorusso D; Gennigens C; González-Martín A; Randall L; Cibula D; Lund B; Woelber L; Pignata S; Forget F; Redondo A; Vindeløv SD; Chen M; Harris JR; Smith M; Nicacio LV; Teng MSL; Laenen A; Rangwala R; Manso L; Mirza M; Monk BJ; Vergote I;
Lancet Oncol; 2021 May; 22(5):609-619. PubMed ID: 33845034
[TBL] [Abstract][Full Text] [Related]
3. Tisotumab Vedotin in Combination With Carboplatin, Pembrolizumab, or Bevacizumab in Recurrent or Metastatic Cervical Cancer: Results From the innovaTV 205/GOG-3024/ENGOT-cx8 Study.
Vergote I; Van Nieuwenhuysen E; O'Cearbhaill RE; Westermann A; Lorusso D; Ghamande S; Collins DC; Banerjee S; Mathews CA; Gennigens C; Cibula D; Tewari KS; Madsen K; Köse F; Jackson AL; Boere IA; Scambia G; Randall LM; Sadozye A; Baurain JF; Gort E; Zikán M; Denys HG; Ottevanger N; Forget F; Mondrup Andreassen C; Eaton L; Chisamore MJ; Viana Nicacio L; Soumaoro I; Monk BJ
J Clin Oncol; 2023 Dec; 41(36):5536-5549. PubMed ID: 37651655
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic Potential of Tisotumab Vedotin in the Treatment of Recurrent or Metastatic Cervical Cancer: A Short Report on the Emerging Data.
Agostinelli V; Musacchio L; Camarda F; Salutari V; Carbone MV; Ghizzoni V; Nero C; Ricci C; Perri MT; Giudice E; Lardino S; Berardi R; Scambia G; Lorusso D
Cancer Manag Res; 2023; 15():1063-1072. PubMed ID: 37790898
[TBL] [Abstract][Full Text] [Related]
5. A Review of Tisotumab Vedotin-tftv in Recurrent or Metastatic Cervical Cancer.
Heitz N; Greer SC; Halford Z
Ann Pharmacother; 2023 May; 57(5):585-596. PubMed ID: 35962528
[TBL] [Abstract][Full Text] [Related]
6. A review of the novel tissue factor antibody-drug conjugate: Tisotumab vedotin.
Luu K; Chu A; Chang B
J Oncol Pharm Pract; 2023 Mar; 29(2):441-449. PubMed ID: 36415085
[TBL] [Abstract][Full Text] [Related]
7. Tisotumab vedotin for the treatment of cervical carcinoma.
Song X; Li R; Wang H; Song P; Guo W; Chen ZS
Drugs Today (Barc); 2022 May; 58(5):213-222. PubMed ID: 35535813
[TBL] [Abstract][Full Text] [Related]
8. Tisotumab vedotin in Japanese patients with recurrent/metastatic cervical cancer: Results from the innovaTV 206 study.
Yonemori K; Kuboki Y; Hasegawa K; Iwata T; Kato H; Takehara K; Hirashima Y; Kato H; Passey C; Buchbjerg JK; Harris JR; Andreassen CM; Nicacio L; Soumaoro I; Fujiwara K
Cancer Sci; 2022 Aug; 113(8):2788-2797. PubMed ID: 35633184
[TBL] [Abstract][Full Text] [Related]
9. Tisotumab Vedotin: First Approval.
Markham A
Drugs; 2021 Dec; 81(18):2141-2147. PubMed ID: 34748188
[TBL] [Abstract][Full Text] [Related]
10. Tisotumab Vedotin in Previously Treated Recurrent or Metastatic Cervical Cancer.
Hong DS; Concin N; Vergote I; de Bono JS; Slomovitz BM; Drew Y; Arkenau HT; Machiels JP; Spicer JF; Jones R; Forster MD; Cornez N; Gennigens C; Johnson ML; Thistlethwaite FC; Rangwala RA; Ghatta S; Windfeld K; Harris JR; Lassen UN; Coleman RL
Clin Cancer Res; 2020 Mar; 26(6):1220-1228. PubMed ID: 31796521
[TBL] [Abstract][Full Text] [Related]
11. Tisotumab vedotin in patients with advanced or metastatic solid tumours (InnovaTV 201): a first-in-human, multicentre, phase 1-2 trial.
de Bono JS; Concin N; Hong DS; Thistlethwaite FC; Machiels JP; Arkenau HT; Plummer R; Jones RH; Nielsen D; Windfeld K; Ghatta S; Slomovitz BM; Spicer JF; Yachnin J; Ang JE; Mau-Sørensen PM; Forster MD; Collins D; Dean E; Rangwala RA; Lassen U
Lancet Oncol; 2019 Mar; 20(3):383-393. PubMed ID: 30745090
[TBL] [Abstract][Full Text] [Related]
12. Population pharmacokinetic analysis for tisotumab vedotin in patients with locally advanced and/or metastatic solid tumors.
Gibiansky L; Passey C; Voellinger J; Gunawan R; Hanley WD; Gupta M; Winter H
CPT Pharmacometrics Syst Pharmacol; 2022 Oct; 11(10):1358-1370. PubMed ID: 35932175
[TBL] [Abstract][Full Text] [Related]
13. Tisotumab Vedotin Safety and Tolerability in Clinical Practice: Managing Adverse Events.
Arn CR; Halla KJ; Gill S
J Adv Pract Oncol; 2023 Mar; 14(2):139-152. PubMed ID: 37009403
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness of tisotumab vedotin as a second- or third-line therapy for cervical cancer.
Huo G; Liu W; Chen P
J Gynecol Oncol; 2024 Jan; ():. PubMed ID: 38330381
[TBL] [Abstract][Full Text] [Related]
15. Mitigation and management strategies for ocular events associated with tisotumab vedotin.
Kim SK; Ursell P; Coleman RL; Monk BJ; Vergote I
Gynecol Oncol; 2022 May; 165(2):385-392. PubMed ID: 35277279
[TBL] [Abstract][Full Text] [Related]
16. Exposure-safety and exposure-efficacy analyses for tisotumab vedotin for patients with locally advanced or metastatic solid tumors.
Passey C; Voellinger J; Gibiansky L; Gunawan R; Nicacio L; Soumaoro I; Hanley WD; Winter H; Gupta M
CPT Pharmacometrics Syst Pharmacol; 2023 Sep; 12(9):1262-1273. PubMed ID: 37496366
[TBL] [Abstract][Full Text] [Related]
17. A randomized phase III trial of platinum chemotherapy plus paclitaxel with bevacizumab and atezolizumab versus platinum chemotherapy plus paclitaxel and bevacizumab in metastatic (stage IVB), persistent, or recurrent carcinoma of the cervix: the BEATcc study (ENGOT-Cx10/GEICO 68-C/JGOG1084/GOG-3030).
Grau JF; Farinas-Madrid L; Oaknin A
Int J Gynecol Cancer; 2020 Jan; 30(1):139-143. PubMed ID: 31645423
[TBL] [Abstract][Full Text] [Related]
18. Integrating antibody drug conjugates in the management of gynecologic cancers.
Chelariu-Raicu A; Mahner S; Moore KN; Lorusso D; Coleman RL
Int J Gynecol Cancer; 2023 Mar; 33(3):420-429. PubMed ID: 36878560
[TBL] [Abstract][Full Text] [Related]
19. Top advances of the year: Cervical cancer.
Podwika SE; Duska LR
Cancer; 2023 Mar; 129(5):657-663. PubMed ID: 36609769
[TBL] [Abstract][Full Text] [Related]
20. Recurrent or primary metastatic cervical cancer: current and future treatments.
Gennigens C; Jerusalem G; Lapaille L; De Cuypere M; Streel S; Kridelka F; Ray-Coquard I
ESMO Open; 2022 Oct; 7(5):100579. PubMed ID: 36108558
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
